Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study
- Resource Type
- Article
- Source
- In
The Lancet Respiratory Medicine September 2021 9(9):977-988 - Subject
Primary Research Articles - Language
- ISSN
- 2213-2600